Sugi Predict

Sugi Predict / Compounds / SCHEMBL7327979

SCHEMBL7327979

SCHEMBL7327979

Brc1cn2ccnc2c(N2CCOCC2)n1

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.70
▸ PIK3CA P42336 3/20 0.60
▸ PIK3R1 P27986 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ AURKA O14965 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.39
▸ RAF1 P04049 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ CD63 P08962 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16094859 0.82 PIK3CA (0.60) HTR2CPIK3CAPIK3R1AURKAPDE10A
SCHEMBL29893256 0.81 HTR2C (0.68) HTR2CPIK3CAPIK3R1TSHRL3MBTL1
SCHEMBL30753350 0.80 HTR2C (0.67) HTR2CPIK3CAPIK3R1L3MBTL1PDE10A
SCHEMBL7324694 0.79 PIK3R1 (0.55) HTR2CPIK3CAPIK3R1PDE10APOLB
SCHEMBL19341969 0.78 HTR2C (0.50) HTR2CPIK3CAPIK3R1RAF1BRAF
SCHEMBL16155955 0.77 PIK3CA (0.54) HTR2CPIK3CAPIK3R1ALDH1A1MAPK1
SCHEMBL10092233 0.77 PIK3CA (0.55) HTR2CPIK3CAPIK3R1ALDH1A1MAPK1
SCHEMBL20005722 0.76 AURKA (0.65) AURKACD63SYK
SCHEMBL15603021 0.75 PIK3CA (1.00) PIK3CAPIK3R1
SCHEMBL2448071 0.74 PIK3CA (0.41) HTR2CPIK3CAPIK3R1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 — — EP disclosed
CN-118974036-A Inhibitors of RAF kinase 皮埃尔法布雷医药公司 2024-11-15 — — CN disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 — — US disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 — — US disclosed
WO-2023150681-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2023-08-10 — — WO disclosed
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-8802850-B2 Cyclopropyl modulators of P2Y12 receptor AUSPEX PHARMACEUTICALS, INC. (US) 2014-08-12 — — US disclosed
US-5028605-A Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives L'UNIVERSITE DE MONTPELLIER I (FR) 1991-07-02 — — US disclosed
EP-0348392-A1 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY Université Montpellier I (FR) 1990-01-03 — — EP disclosed
WO-1988004298-A1 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1988-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF HTR2C 4352/4885PIK3CA 61/4885PIK3R1 107/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS HTR2C 4552/4885PIK3CA 44/4885PIK3R1 196/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS HTR2C 4552/4885PIK3CA 44/4885PIK3R1 196/4885
US-11814384-B2 Inhibtors of Raf kinases RAF1, BRAF, ARAF HTR2C 4334/4885PIK3CA 114/4885PIK3R1 59/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS HTR2C 4552/4885PIK3CA 44/4885PIK3R1 196/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS HTR2C 4552/4885PIK3CA 44/4885PIK3R1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.